Chong Kun Dang Pharmaceutical Corp.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1941-01-01
- Employees
- 2.3K
- Market Cap
- -
- Website
- http://www.ckdpharm.com
Evaluate the Glycemic Control of CKD-501 in Type 2 Diabetes Mellitus
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: CKD-501 0.5mgDrug: PlaceboDrug: CKD-501 2mgDrug: CKD-501 1mg
- First Posted Date
- 2009-12-11
- Last Posted Date
- 2009-12-16
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 214
- Registration Number
- NCT01030679
- Locations
- 🇰🇷
The Yeungnam University Hospital, Daegu, Korea, Republic of
🇰🇷The Korea University Anam Hospital, Seoul, Korea, Republic of
🇰🇷The Inje University Medical Center, Busan, Korea, Republic of
Dyslipidemia in Cardiovascular Disease
Phase 4
Completed
- Conditions
- Dyslipidemia
- Interventions
- First Posted Date
- 2009-12-10
- Last Posted Date
- 2012-08-09
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 244
- Registration Number
- NCT01029522
Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid Cancers
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Drug: CKD-516 inj
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2011-12-22
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 30
- Registration Number
- NCT01028859
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Study of Camtobell Inj (Belotecan) on Weekly Schedule in Non-small Cell Lung Cancer (NSCLC) Patients Previously Treated With Chemotherapy
- First Posted Date
- 2009-12-01
- Last Posted Date
- 2016-01-28
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 52
- Registration Number
- NCT01022671
Pharmacokinetic Study of CKD-810 and Taxotere to Treat Patient With Advanced Solid Cancer
Phase 1
Completed
- Conditions
- Advanced Solid Cancers
- Interventions
- Drug: CKD-810, Taxotere inj.
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2010-12-16
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 44
- Registration Number
- NCT01019941
- Locations
- 🇰🇷
Ajou University Hospital, Suwon, Korea, Republic of
🇰🇷The Korea University Anam Hospital, Seoul, Korea, Republic of
🇰🇷Gachon University Gil Hospital, Inchon, Korea, Republic of
Study to Evaluate the Pharmacokinetic Characteristics of CKD-4101 (Mycophenolate Mofetil) Tablet
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: CKD-4101 tablet
- First Posted Date
- 2009-11-19
- Last Posted Date
- 2009-11-19
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 28
- Registration Number
- NCT01016626
- Locations
- 🇰🇷
The Korea University Anam Hospital, Seoul, Korea, Republic of
Drug Interaction Between CKD-501 and Metformin
- First Posted Date
- 2009-10-30
- Last Posted Date
- 2011-01-12
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 24
- Registration Number
- NCT01005160
An Evaluation of Glycemic Control Effects of Mono Therapy CKD-501 in Patients With Type 2 Diabetes Mellitus
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: CKD-501 0.5mgDrug: Placebo
- First Posted Date
- 2009-10-26
- Last Posted Date
- 2013-07-19
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 173
- Registration Number
- NCT01001611
- Locations
- 🇰🇷
The Hallym University Medical Center, Seoul, Korea, Republic of
🇰🇷The Korea University Anam Hospital, Seoul, Korea, Republic of
🇰🇷The Kyung Hee University Medical Center, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath